National University Hospital
5 Lower Kent Ridge Road
Singapore 119074
www.nuh.com.sg
Tel: (65) 6772 4346
Fax: (65) 6775 1757

MEMORANDUM

To : All RAPIDPoint 500e (RP500e) Blood Gas System Users

From : Department of Laboratory Medicine

Date : 23 October 2023

Re : **Atomoxetine Hydrochloride Interference on Sodium Measurement reported by the RAPIDPoint 500e (RP500e) Blood Gas System**

Dear Users,

Siemens Healthcare Diagnostics Inc. has determined that Atomoxetine Hydrochloride may interfere with sodium results reported on the RP500e Blood Gas System.
The RP500e blood gas systems are deployed in wards 20, 21, 22, 23, 24, 26,27,28, 29, 46 and main building Operating theatres offering Point-of-Care blood gas analysis.

The presence of atomoxetine hydrochloride has the potential to **erroneously elevate** sodium results which may lead to unrecognized hyponatremia and/or the inappropriate treatment of hypernatremia.

Tables below summarises the effect on samples that contain Atomoxetine Hydrochloride.

Interference Observed on Sodium Results on the RAPIDPoint 500e Blood Gas System

Substance	Concentration Tested (mg/dL)	Level of Interference on Sodium (mmol/L)
Atomoxetine Hydrochloride	≥ 0.04	> + 2.0

Mitigations by Siemens Healthcare Diagnostics suggests the short time-interval testing needs to occur after drug dosing for atomoxetine hydrochloride due to its short half-life, correlation of results with other electrolyte results such as chloride, historical sodium results, and the clinical history of the patient or to send a blood sample to the clinical laboratory for electrolyte testing.

Please contact the POCT team at 67722017 for further enquiries

Yours sincerely

Dr Sharon Saw
Principal Scientific Officer
Department of Laboratory Medicine